Atea sticks it out with failed COVID-19 antiviral but also raids Merck's store room...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 07, 2022 at 11:02: AM
via Atea Pharmaceuticals is still determined to get its COVID-19 antiviral through clinical trials, but without a partner to collaborate with, the biotech is also raiding Merck's store room to make a play in a different indication.

article source
 

<



Similar threads

cafead
Concentra finds latest acquisition attempt harder to swallow as Atea rejects...
Replies
0
Views
175
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Concentra rebounds from Jounce buy with a shot at COVID-19-focused Atea
Replies
0
Views
268
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Atea dumps dengue drug as &#039;unevaluable&#039; endpoint causes timelines, forecast costs...
Replies
0
Views
93
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Atea’s antiviral pill fails to clear Covid-19, forcing a re-think
Replies
0
Views
129
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Atea, riding interest in COVID-19 drugs, pulls off one of 2020&#039;s top biotech IPOs
Replies
0
Views
140
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote